国际投行报告-中国医疗保健行业-在竞争激烈的比赛中选择长期的赢家-2021.10.25-45页

438

国际投行报告-中国医疗保健行业-在竞争激烈的比赛中选择长期的赢家-2021.10.25-45页

# 医疗保健 # 国际投行大小：1.08M | 页数：45 | 上架时间：2021-11-03 | 语言：英文

国际投行报告-中国医疗保健行业-在竞争激烈的比赛中选择长期的赢家-2021.10.25-45页.pdf

免费阅读10页，购买之后可查看、下载45页完整报告

国际投行报告-中国医疗保健行业-在竞争激烈的比赛中选择长期的赢家-2021.10.25-45页.pdf

试看10页

类型: 行研

上传者: 资料分享客栈

撰写机构: CREDIT SUISSE

出版日期: 2021-10-25

摘要：

China PD-1/PD-L1 market is expected to maintain good growth in next few years with increasing competition. PD-1 drugs have become the most important innovative drug class in China with a combined sales of Rmb11-12 bn in 2020. Competition is increasing as there are 10 approved PD-1/PD-L1 drugs in China with a few more expected to come. We estimate the China PD-1 market to grow to Rmb40-45 bn in 10 years. We assume a long-term annual pricing of ≥Rmb30k, which corresponds to ~1.3 mn patients on PD-1 at peak. We also believe MNC (multinational corporation)’s PD-1 market share in China would continue to fall due to speedy indication expansion and price advantage from domestic players.

展开>> 收起<<

请登录，再发表你的看法

资料分享客栈

关注